Barely Significant
← all phrases

“showed a trend”

53,323 sentences · 53,323 papers · 65,371 search hits before verification

In the literature

A phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated mCRC (CALGB/SWOG80405), in which the primary endpoint was OS, showed no significant difference in the combination of chemotherapy with cetuximab or bevacizumab, but it showed a trend toward longer OS in cetuximab-treated patients versus bevacizumab-treated patients with FOLFOX [ 5 ].
77 and 76 years, respectively). 18 Additionally, a 50% dose reduction of NOACs in patients with a CrCl >50 mL/min is more likely to result in insufficient drug exposure compared with a 25% dose reduction. These findings were similar to those from a Danish national cohort study, which showed a trend toward a higher risk of stroke/SE with the reduced dose of apixaban (4.8%), and a trend toward a lower risk of stroke/SE with the lower dose of dabigatran (3.3%) and rivaroxaban (3.5%), compared with warfarin (3.7%) at 1-year follow-up.